The drug-induced modulation of the Bax/Bcl-2 expression ratio (up-regulation of Bax, down-regulation of Bcl-2), associated with a release of cytochrome c and caspases activation has been clearly evidenced using colon [53], hepatocellular [55] and breast [56] cancer cells. This evidence concerns the gene BCL2 and cancer.